{"id":"daunorubicine","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Bacterial infectious disease","Bone marrow depression","Breastfeeding (mother)","Cardiomyopathy","Chronic heart failure","Conduction disorder of the heart","Disease of liver","Epilepsy","Granulocytopenic disorder","Hyperuricemia","Kidney disease","Mycosis","Myocarditis","Neutropenic disorder","Pericarditis","Pregnancy, function","Protozoal Infection","Ventricular tachycardia","Viral disease"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT02626455","NCT02722135","NCT01940497","NCT00525759","NCT03446638","NCT00002791","NCT01692197","NCT01985724","NCT02269579","NCT06470633","NCT00003934","NCT07424287","NCT03226249","NCT00005830","NCT00006034","NCT00895414","NCT00416598","NCT00003084","NCT00482833","NCT00135499","NCT01670084","NCT00209833","NCT07223814","NCT02789332","NCT00877006","NCT00795899","NCT04138719","NCT02372409","NCT00002526","NCT07156435","NCT00191789","NCT00080782","NCT06526923","NCT05020860","NCT00577096","NCT06468943","NCT00931918","NCT01085617","NCT07072585","NCT00004231","NCT05420467","NCT06291064","NCT00016302","NCT03349957","NCT01607645","NCT04762901","NCT02177695","NCT00121992","NCT06345365","NCT01659554"],"aliases":["DSP-DNR"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"Daunorubicin is a chemotherapy medication used to treat various types of cancer, including leukemia and sarcoma, typically administered by injection into a vein. It works as a DNA topoisomerase II alpha inhibitor, a small molecule that targets and inhibits this enzyme.","brandName":"Daunorubicine","companyId":"gruppo-italiano-malattie-ematologiche-dell-adulto","ecosystem":[],"mechanism":{"target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Gruppo Italiano Malattie EMatologiche dell'Adulto","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Daunorubicine","indications":{"approved":[{"name":"Acute lymphoid leukemia","diseaseId":"acute-lymphoid-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute monocytic/monoblastic leukemia","diseaseId":"acute-monocytic/monoblastic-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute myeloid leukemia, disease","diseaseId":"acute-myeloid-leukemia-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute promyelocytic leukemia, FAB M3","diseaseId":"acute-promyelocytic-leukemia-fab-m3","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Blast crisis of chronic myeloidleukemia","diseaseId":"blast-crisis-of-chronic-myeloidleukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythroleukemia, FAB M6","diseaseId":"erythroleukemia-fab-m6","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Kaposi's sarcoma","diseaseId":"kaposi's-sarcoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02626455","phase":"Phase 3","title":"A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patie","status":"TERMINATED","sponsor":"Bayer","isPivotal":true,"enrollment":551,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2023-11-10"},{"nctId":"NCT02722135","phase":"Phase 1","title":"Open-label, Dose-escalating Trial to Evaluate the Tolerability, Toxicity, Safety, Pharmacokinetics, Pharmacodynamics and Activity of Volasertib Added to the Standard Intensive Salvage Chemotherapy Reg","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":0,"indication":"Leukemia, Myeloid, Acute","completionDate":"2018-09"},{"nctId":"NCT01940497","phase":"Phase 3","title":"National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally A","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":240,"indication":"Breast Cancer","completionDate":"2018-03-27"},{"nctId":"NCT00525759","phase":"Phase 2","title":"A Randomised Phase II Feasibility Study Investigating the Biological Effects of the Addition of Zoledronic Acid to Neoadjuvant Combination Chemotherapy on Invasive Breast Cancer","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","isPivotal":false,"enrollment":40,"indication":"Breast Cancer","completionDate":"2010-01"},{"nctId":"NCT03446638","phase":"NA","title":"iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"University of Florida","isPivotal":false,"enrollment":0,"indication":"Myelodysplastic Syndromes","completionDate":"2022-09"},{"nctId":"NCT00002791","phase":"Phase 2","title":"A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY WALL","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","isPivotal":false,"enrollment":0,"indication":"Sarcoma","completionDate":"2013-11"},{"nctId":"NCT01692197","phase":"Phase 2","title":"A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":43,"indication":"Leukemia","completionDate":"2017-06-07"},{"nctId":"NCT01985724","phase":"Phase 3","title":"A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-supported Sequential Administration of FE75C Followed by Docetaxel Versus Docetaxel/Cyclophosphamide Doublet as Adjuvant Chemotherapy in ","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","isPivotal":true,"enrollment":650,"indication":"Breast Cancer","completionDate":"2013-12"},{"nctId":"NCT02269579","phase":"Phase 2","title":"An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepa","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","isPivotal":false,"enrollment":0,"indication":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)","completionDate":"2017-06"},{"nctId":"NCT06470633","phase":"Phase 2","title":"To Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy Neoadjuvant Therapy in Early or Local Advanced Breast Cancer After Induction Treatment of High-intensity Focused Ultrasoun","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","isPivotal":false,"enrollment":29,"indication":"Breast Cancer, HR+/HER2- Breast Cancer","completionDate":"2026-12-31"},{"nctId":"NCT00003934","phase":"Phase 3","title":"Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Interm","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":true,"enrollment":420,"indication":"Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3)","completionDate":""},{"nctId":"NCT07424287","phase":"Phase 3","title":"A Multicenter, Randomized, Open-label Phase III Clinical Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Investigator-selected Chemotherapy In Patients With BCG-unre","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","isPivotal":true,"enrollment":236,"indication":"NMIBC","completionDate":"2030-06"},{"nctId":"NCT03226249","phase":"Phase 2","title":"Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","isPivotal":false,"enrollment":30,"indication":"Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma","completionDate":"2024-10"},{"nctId":"NCT00005830","phase":"Phase 1","title":"Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","isPivotal":false,"enrollment":31,"indication":"Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma","completionDate":""},{"nctId":"NCT00006034","phase":"Phase 3","title":"A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Re","status":"COMPLETED","sponsor":"Intracel","isPivotal":true,"enrollment":0,"indication":"Bladder Cancer","completionDate":"2004-03"},{"nctId":"NCT00895414","phase":"NA","title":"The Effect of Enalapril on Doxorubicin Exposure in Adjuvant Breast Cancer Treatment","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","isPivotal":false,"enrollment":19,"indication":"Breast Cancer","completionDate":"2015-10"},{"nctId":"NCT00416598","phase":"Phase 2","title":"Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML &lt; 60 Years","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":546,"indication":"Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes","completionDate":"2016-12-01"},{"nctId":"NCT00003084","phase":"Phase 2","title":"A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. Ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":75,"indication":"Prostate Cancer","completionDate":"2002-11"},{"nctId":"NCT00482833","phase":"Phase 3","title":"A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promye","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","isPivotal":true,"enrollment":276,"indication":"Leukemia","completionDate":"2019-10-17"},{"nctId":"NCT00135499","phase":"Phase 3","title":"Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma","status":"TERMINATED","sponsor":"Lymphoma Study Association","isPivotal":true,"enrollment":138,"indication":"Lymphoma, Large-Cell, Diffuse","completionDate":"2010-04-27"},{"nctId":"NCT01670084","phase":"Phase 2","title":"A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid","status":"WITHDRAWN","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":0,"indication":"B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia","completionDate":"2017-09"},{"nctId":"NCT00209833","phase":"Phase 2","title":"Protocol for the Treatment of Adults Aged </= 60 Years With De Novo Acute Myeloblastic Leukaemia or Secondary AML or RAEB-T (AML 01/99 Trial)","status":"UNKNOWN","sponsor":"Hannover Medical School","isPivotal":true,"enrollment":200,"indication":"De Novo Akute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML)","completionDate":"2005-09"},{"nctId":"NCT07223814","phase":"Phase 3","title":"Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute ","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","isPivotal":true,"enrollment":875,"indication":"Acute Myeloid Leukemia","completionDate":"2033-12"},{"nctId":"NCT02789332","phase":"Phase 2","title":"A Randomized Phase II Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients ","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","isPivotal":false,"enrollment":107,"indication":"Breast Cancer, Triple Negative Breast Neoplasms","completionDate":"2020-02"},{"nctId":"NCT00877006","phase":"Phase 3","title":"An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosp","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","isPivotal":true,"enrollment":447,"indication":"Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma","completionDate":"2012-03-31"},{"nctId":"NCT00795899","phase":"Phase 2","title":"Preoperative Therapy With Epirubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab and Postoperative Therapy With Trastuzumab in Patients With HER-2 Over Expressed Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","isPivotal":false,"enrollment":230,"indication":"Breast Cancer","completionDate":"2008-09"},{"nctId":"NCT04138719","phase":"Phase 2","title":"Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","isPivotal":false,"enrollment":520,"indication":"Breast Cancer, Triple-negative Breast Cancer","completionDate":"2028-06-20"},{"nctId":"NCT02372409","phase":"Phase 2","title":"A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors","status":"TERMINATED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":6,"indication":"Glioma, Pilocytic Astrocytoma","completionDate":"2023-03-23"},{"nctId":"NCT00002526","phase":"Phase 2","title":"Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma","status":"COMPLETED","sponsor":"Swiss Cancer Institute","isPivotal":false,"enrollment":20,"indication":"Ovarian Cancer, Sarcoma","completionDate":"1995-09"},{"nctId":"NCT07156435","phase":"Phase 1","title":"A Phase lb Study of Vyxeos® (Liposomal Daunorubicin and Cytarabine) in Combination With Clofarabine in Children With Relapsed/Refractory AML, ITCC-092","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","isPivotal":false,"enrollment":25,"indication":"Relapsed Pediatric AML, Refractory Pediatric AML","completionDate":"2028-12-31"},{"nctId":"NCT00191789","phase":"Phase 2","title":"Neoadjuvant Administration of Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Large or Locally Advanced Operable Breast Cancer: A Phase II Study","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":65,"indication":"Breast Cancer","completionDate":"2009-04"},{"nctId":"NCT00080782","phase":"Phase 2","title":"A Randomized Phase II Trial of Bone-Targeted Therapy Consisting of Strontium-89 and Doxorubicin With or Without Celecoxib in Androgen-Independent Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":14,"indication":"Metastatic Cancer, Prostate Cancer","completionDate":"2005-01"},{"nctId":"NCT06526923","phase":"Phase 1","title":"A Single Ascending Dose, Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of SP-101 Via Nebulizer for the Treatment of Cystic Fibrosis (CF)","status":"RECRUITING","sponsor":"Spirovant Sciences, Inc.","isPivotal":false,"enrollment":15,"indication":"Cystic Fibrosis","completionDate":"2026-12-31"},{"nctId":"NCT05020860","phase":"Phase 2","title":"A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer","status":"RECRUITING","sponsor":"Baylor Breast Care Center","isPivotal":false,"enrollment":185,"indication":"Breast Cancer, Breast Neoplasm","completionDate":"2029-11"},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","isPivotal":false,"enrollment":120,"indication":"Multiple Myeloma","completionDate":"2004-06"},{"nctId":"NCT06468943","phase":"Phase 2","title":"Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients in Treatment of Newly Diagnosed Untreated Non-GCB DLBCL With Extranodal Involvement.","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital of Soochow University","isPivotal":false,"enrollment":20,"indication":"Effects of Chemotherapy, Safety Issues","completionDate":"2028-05-01"},{"nctId":"NCT00931918","phase":"Phase 2","title":"An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","isPivotal":false,"enrollment":206,"indication":"Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)","completionDate":"2015-08"},{"nctId":"NCT01085617","phase":"N/A","title":"A Randomized Trial for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","isPivotal":false,"enrollment":0,"indication":"Leukemia, Mucositis","completionDate":"2025-02-24"},{"nctId":"NCT07072585","phase":"Phase 2","title":"A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","isPivotal":true,"enrollment":1708,"indication":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma","completionDate":"2035-09-01"},{"nctId":"NCT00004231","phase":"Phase 2","title":"Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":0,"indication":"Lymphoma","completionDate":"2006-08"},{"nctId":"NCT05420467","phase":"Phase 4","title":"A Prospective, Open-label, Non-inferiority Study to Evaluate Injectable Albumin-bound Paclitaxel Versus Docetaxel for the Adjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":2413,"indication":"Breast Cancer","completionDate":"2027-12-20"},{"nctId":"NCT06291064","phase":"Phase 2","title":"TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)","status":"RECRUITING","sponsor":"University of Chicago","isPivotal":false,"enrollment":85,"indication":"Triple Negative Breast Cancer","completionDate":"2032-06"},{"nctId":"NCT00016302","phase":"NA","title":"The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":100,"indication":"T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia","completionDate":""},{"nctId":"NCT03349957","phase":"N/A","title":"Retrospective Study on TACE for HCC by TANDEM and Idarubicin","status":"COMPLETED","sponsor":"University Hospital, Montpellier","isPivotal":false,"enrollment":98,"indication":"Hepatocellular Carcinoma (HCC)","completionDate":"2018-03-30"},{"nctId":"NCT01607645","phase":"Phase 2","title":"Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML.","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":7,"indication":"Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)","completionDate":"2013-09"},{"nctId":"NCT04762901","phase":"Phase 1","title":"LCI-BRE-MTN-NIR-001: A Phase I Study of Niraparib in Combination With Standard Chemotherapy in Metastatic Triple-Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","isPivotal":false,"enrollment":0,"indication":"Breast Cancer","completionDate":"2026-01"},{"nctId":"NCT02177695","phase":"Phase 2","title":"A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","isPivotal":false,"enrollment":237,"indication":"Bladder Cancer","completionDate":"2022-12-01"},{"nctId":"NCT00121992","phase":"Phase 3","title":"Phase III Randomized Comparing Docetaxel, Doxorubicin and Cyclophosphamide (TAC) vs 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Pat","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","isPivotal":true,"enrollment":1060,"indication":"Breast Neoplasms","completionDate":"2013-03-06"},{"nctId":"NCT06345365","phase":"Phase 3","title":"A Prospective, Multicenter, Randomized Controlled Study on the MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Zhongnan Hospital","isPivotal":true,"enrollment":154,"indication":"Acute Myeloid Leukaemia","completionDate":"2028-12-31"},{"nctId":"NCT01659554","phase":"Phase 2","title":"A Phase II Combined Modality Protocol of Debulking Surgery With Heated Intraoperative Chemotherapy (HIPEC) Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peri","status":"TERMINATED","sponsor":"Columbia University","isPivotal":false,"enrollment":4,"indication":"Recurrent Ovarian Cancer, Fallopian Tube Cancer","completionDate":"2014-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}